4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $33.25 Consensus PT from Brokerages

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been given a consensus recommendation of “Moderate Buy” by the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $32.8571.

FDMT has been the topic of a number of research reports. Barclays initiated coverage on shares of 4D Molecular Therapeutics in a report on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 price objective for the company. Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Royal Bank Of Canada reiterated an “outperform” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 7th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Finally, Morgan Stanley raised 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th.

4D Molecular Therapeutics Stock Up 5.6%

4D Molecular Therapeutics stock opened at $8.93 on Monday. The firm has a 50 day moving average price of $8.51 and a 200-day moving average price of $8.95. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $12.34. The company has a market capitalization of $510.17 million, a P/E ratio of -2.38 and a beta of 2.99.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Martingale Asset Management L P raised its position in 4D Molecular Therapeutics by 12.4% during the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock valued at $88,000 after purchasing an additional 1,303 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of 4D Molecular Therapeutics by 3.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 58,006 shares of the company’s stock valued at $504,000 after purchasing an additional 2,069 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of 4D Molecular Therapeutics by 11.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock valued at $81,000 after buying an additional 2,284 shares in the last quarter. Prelude Capital Management LLC lifted its position in 4D Molecular Therapeutics by 11.1% in the 3rd quarter. Prelude Capital Management LLC now owns 23,000 shares of the company’s stock worth $200,000 after buying an additional 2,300 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in 4D Molecular Therapeutics by 117.4% in the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after buying an additional 2,674 shares in the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.